The results showed that MAP2K1 mutations were associated with a higher prevalence of SS‐bone LCH, while BRAF exon 12 deletions were correlated with an increased risk of lung involvement [4]. The gene discussed is MAP2K1; the disease is Langerhans cell histiocytosis.